For example, ibrutinib, a Bruton’s tyrosine kinase inhibitor, suppresses IMQ-induced psoriasis-like skin inflammation in mice by downregulating IL-17A and IL-23 expression (Nadeem et al., 2020a). This evidence concerns the gene IL17A and psoriasis.